<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mariateresa Coppola</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Fabienne Jurion</style></author><author><style face="normal" font="default" size="100%">Tima, Hermann Giresse</style></author><author><style face="normal" font="default" size="100%">Marta Romano</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">Susan J F Van den Eeden</style></author><author><style face="normal" font="default" size="100%">Franken, Kees L M C</style></author><author><style face="normal" font="default" size="100%">Annemieke Geluk</style></author><author><style face="normal" font="default" size="100%">Ottenhoff, Tom H M</style></author></tertiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">In-vivo expressed Mycobacterium tuberculosis antigens recognised in three mouse strains after infection and BCG vaccination.</style></title><secondary-title><style face="normal" font="default" size="100%">NPJ Vaccines</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 Jun 03</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">6</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Novel tuberculosis (TB)-vaccines preferably should (i) boost host immune responses induced by previous BCG vaccination and (ii) be directed against Mycobacterium tuberculosis (Mtb) proteins expressed throughout the Mtb infection-cycle. Human Mtb antigen-discovery screens identified antigens encoded by Mtb-genes highly expressed during in vivo murine infection (IVE-TB antigens). To translate these findings towards animal models, we determined which IVE-TB-antigens are recognised by T-cells following Mtb challenge or BCG vaccination in three different mouse strains. Eleven Mtb-antigens were recognised across TB-resistant and susceptible mice. Confirming previous human data, several Mtb-antigens induced cytokines other than IFN-γ. Pulmonary cells from susceptible C3HeB/FeJ mice produced less TNF-α, agreeing with the TB-susceptibility phenotype. In addition, responses to several antigens were induced by BCG in C3HeB/FeJ mice, offering potential for boosting. Thus, recognition of promising Mtb-antigens identified in humans validates across multiple mouse TB-infection models with widely differing TB-susceptibilities. This offers translational tools to evaluate IVE-TB-antigens as diagnostic and vaccine antigens.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record></records></xml>